Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes

Rimke C. Vos; Guy E.H.M. Rutten

doi:10.1001/jama.2017.13463

Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Clinical Question: Among patients with type 2 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured by lowering of hemoglobin A1c) or adverse effects?

Bottom Line: Adding a sulfonylurea to insulin was associated with more hypoglycemic events compared with insulin alone, but this association was not observed for metformin. Adding a sulfonylurea or metformin to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%.

Original language	English
Pages (from-to)	1489-1490
Number of pages	2
Journal	JAMA - The Journal of The American Medical Association
Volume	318
Issue number	15
DOIs	https://doi.org/10.1001/jama.2017.13463
Publication status	Published - 17 Oct 2017

Keywords

Journal Article

Access to Document

10.1001/jama.2017.13463

Cite this

@article{301b07cadc62435883895b1b6ee9a1f6,

title = "Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes",

abstract = "Clinical Question: Among patients with type 2 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured by lowering of hemoglobin A1c) or adverse effects?Bottom Line: Adding a sulfonylurea to insulin was associated with more hypoglycemic events compared with insulin alone, but this association was not observed for metformin. Adding a sulfonylurea or metformin to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%.",

keywords = "Journal Article",

author = "Vos, {Rimke C.} and Rutten, {Guy E.H.M.}",

note = "Funding Information: have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Vos reported receiving unrestricted research grants from Sanofi and the European Foundation for the Study of Diabetes. Dr Rutten reported receiving an unrestricted research grant from Sanofi and personal fees from Novo Nordisk.",

year = "2017",

month = oct,

day = "17",

doi = "10.1001/jama.2017.13463",

language = "English",

volume = "318",

pages = "1489--1490",

journal = "JAMA - The Journal of The American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "15",

}

TY - JOUR

T1 - Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes

AU - Vos, Rimke C.

AU - Rutten, Guy E.H.M.

N1 - Funding Information: have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Vos reported receiving unrestricted research grants from Sanofi and the European Foundation for the Study of Diabetes. Dr Rutten reported receiving an unrestricted research grant from Sanofi and personal fees from Novo Nordisk.

PY - 2017/10/17

Y1 - 2017/10/17

N2 - Clinical Question: Among patients with type 2 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured by lowering of hemoglobin A1c) or adverse effects?Bottom Line: Adding a sulfonylurea to insulin was associated with more hypoglycemic events compared with insulin alone, but this association was not observed for metformin. Adding a sulfonylurea or metformin to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%.

AB - Clinical Question: Among patients with type 2 diabetes mellitus who do not achieve optimal glycemic control with insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured by lowering of hemoglobin A1c) or adverse effects?Bottom Line: Adding a sulfonylurea to insulin was associated with more hypoglycemic events compared with insulin alone, but this association was not observed for metformin. Adding a sulfonylurea or metformin to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%.

KW - Journal Article

UR - http://www.scopus.com/inward/record.url?scp=85031849391&partnerID=8YFLogxK

U2 - 10.1001/jama.2017.13463

DO - 10.1001/jama.2017.13463

M3 - Article

C2 - 29049639

SN - 0098-7484

VL - 318

SP - 1489

EP - 1490

JO - JAMA - The Journal of The American Medical Association

JF - JAMA - The Journal of The American Medical Association

IS - 15

ER -

Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this